Johnson Linda M, Rothwax Jason T, Turkbey Baris, Rais-Bahrami Soroush, Wood Bradford J, Figg William D, Choyke Peter L, Merino Maria J, Pinto Peter A
*From the Molecular Pharmacology Section, Medical Oncology Branch, and †Molecular Imaging Program, National Cancer Institute, Bethesda, MD; ‡Urologic Oncology Branch, NCI, NIH, Bethesda, MD; §Center for Interventional Oncology, Radiology and Imaging Sciences CC, NIH, Bethesda, MD; ∥Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and ¶Laboratory of Pathology, NCI, NIH, Bethesda, MD.
J Comput Assist Tomogr. 2014 Jul-Aug;38(4):565-7. doi: 10.1097/RCT.0000000000000069.
Multiparametric magnetic resonance imaging (MRI) provides an accurate anatomical assessment of the tumor and its local staging. Herein, we report a case of intermediate-risk prostatic adenocarcinoma, initially followed on active surveillance, which upgraded from Gleason 7 (3 + 4) to Gleason 8 (4 + 4) on transrectal ultrasound/MRI fusion biopsy after progression of MR spectroscopic findings and review of the role of multiparametric MRI in the follow-up of patients with prostate cancer undergoing active surveillance.
多参数磁共振成像(MRI)可对肿瘤及其局部分期进行准确的解剖学评估。在此,我们报告一例中度风险前列腺腺癌病例,该病例最初接受主动监测,在磁共振波谱结果进展后,经直肠超声/MRI融合活检,其 Gleason 评分从 7(3 + 4)升至 Gleason 8(4 + 4),并探讨了多参数 MRI 在接受主动监测的前列腺癌患者随访中的作用。